The Current Status of Chemotherapy for Advanced Renal Carcinoma

Woodruff, Marvin W.; Wagle, D.C.; Gailani, Salman; Jones, Ralph

doi:10.1016/s0022-5347(17)63087-8

Cited by 49 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Symptomatic improvement and minimal responses from a variety of cytotoxic agents have not improved the survival of patients [1,3,4], VEF combination chemotherapy produced a minimal response (stabilization) in 50% of the patients, although it did not influence their survival. The symptomatic improvement may well have been due to the temporal administration of dexamethasone.…”

Section: Discussionmentioning

confidence: 97%

“…The use of chemotherapeutic drugs, either as single agents, or in various combinations, has shown disap pointing results in the management of metastatic hyper nephroma [1,3,4).…”

Section: Introductionmentioning

confidence: 99%

“…Woodruff et al [4], in 1967, found that cyclophosphamide produced 2/16 responses; 5-fluor ouracil, 5/36 responses, and vinblastine, 1/10 responses. Talley [3), in 1973, reported 2/15 responses with vinblastine, and 7/34 responses with cyclophosphamide.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vinblastine, Cyclophosphamide and 5-Fluorouracil (VEF) Combination Chemotherapy for Metastatic Hypernephroma

Halpern¹,

Brufman²,

Shnider³

et al. 1981

Oncology

View full text Add to dashboard Cite

10 evaluable patients with metastatic hypernephroma received vinblastine (6 mg/m², i.v., on days 1 and 8), cyclophosphamide (100 mg/m², p.o., on days 1–14), and 5-fluorouracil (600 mg/m², i.v., on days 1 and 8), cycled every 29 days. 7 of the patients also received dexamethasone (16 mg/day, p.o.), shortly before or during chemotherapy, in an attempt to improve their clinical status. No complete or partial responses were seen. 5 patients (50%) remained stable (median duration, 4.5 months; median survival, 6.5 months), and the remaining 5 patients progressed. A subjective response was observed in all stable patients, who also received dexamethasone. The side-effects of VEF chemotherapy were mild: 2/10 patients developed leukopenia (WBC below 3,000), 3/10 patients manifested thrombocytopenia (platelets below 100,000), and 3/10 patients alopecia.

show abstract

Section: Discussionmentioning

confidence: 97%

“…The use of chemotherapeutic drugs, either as single agents, or in various combinations, has shown disap pointing results in the management of metastatic hyper nephroma [1,3,4).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vinblastine, Cyclophosphamide and 5-Fluorouracil (VEF) Combination Chemotherapy for Metastatic Hypernephroma

Halpern¹,

Brufman²,

Shnider³

et al. 1981

Oncology

View full text Add to dashboard Cite

show abstract

“…Each of these nine studies includes a progestational agent, except that of Jenkin (13), wluch used androgens alone. The studies range in size There are nine studies in the literature prior to 1971 (2,13,18,22,23,25,(31)(32)(33) or androgenic hormonal therapy (1,7,16,17,30). Two of these studies are randomized ECOG studies (7,16) as is the study of Alberto and Senn (1).…”

Section: Hormonal Therapymentioning

confidence: 99%

Current status of the therapy of advanced renal carcinoma

Hrushesky

Murphy

1977

Journal of Surgical Oncology

165

View full text Add to dashboard Cite

A preclinical murine renal model system is available for evaluation of the effectiveness of therapeutic agents. Clinical review reveals that objective response rates to hormonal agents reported since 1971 have been substantially lower than those reported prior to 1971. Many chemotherapeutic agents have not been adequately evaluated clinically or with the experimental model. Vinblastine to date may be the most active single agent with a 25% objective response rate. At the present time, it is uncertain whether combination chemotherapy or hormonal chemotherapy add to response rates obtained with single agents. There is some evidence that immunotherapy may be of some adjuvant benefit and, thus may provide an additional avenue of investigation.

show abstract

“…Woodruff et al (1967) reviewed the literature on this subject, and of 243 collected cases treated with 33 different non-hormonal agents only 10% showed signs of objective improvement: in most instances this was slight or of brief duration. Talley et al (1969) have published their personal experience with various cytotoxic drugs against metastatic hypernephroma.…”

mentioning

confidence: 99%

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Bloom¹

1971

Br J Cancer

100

View full text Add to dashboard Cite

SUMMARY.-Eighty patients with advanced metastatic renal cancer have been treated with hormones, chiefly medroxyprogesterone acetate (Provera). This progestational compound is remarkably free from side-effects and can be given in high dosage for long periods without serious complications. Ninety per cent of cases had multiple metastases: in 76% more than one organ was involved and nearly 50% were seriously ill or " terminal ".Subjective improvement occurred in at least 55%. BETWEEN 75% and 80% of patients treated for renal cell carcinoma will die within 10 years of their primary treatment, the majority with distant metastases. In a few of these cases the natural history of the disease will be unusual. For example, growth of metastases may be exceptionally slow or, following removal of a solitary lesion, the patient may live for a number of years without further recurrence. Very rarely spontaneous regression of pulmonary deposits may occur. For the vast majority of cases, however, the onset of clinical metastases heralds death within a year or two. The treatment of advanced renal cancer with cytotoxic drugs has been disappointing. Woodruff et al. (1967) reviewed the literature on this subject, and of 243 collected cases treated with 33 different non-hormonal agents only 10% showed signs of objective improvement: in most instances this was slight or of brief duration. Talley et al. (1969) have published their personal experience with various cytotoxic drugs against metastatic hypernephroma. Of 57 patients treated with 15 different non-hormonal compounds, chiefly alkylating agents, antimetabolites and vinblastine, objective improvement was seen in only two cases (3.50 %). Apart from these poor results, the agents employed are highly toxic and have a relatively small margin of safety.

show abstract

The Current Status of Chemotherapy for Advanced Renal Carcinoma

Cited by 49 publications

References 12 publications

Vinblastine, Cyclophosphamide and 5-Fluorouracil (VEF) Combination Chemotherapy for Metastatic Hypernephroma

Vinblastine, Cyclophosphamide and 5-Fluorouracil (VEF) Combination Chemotherapy for Metastatic Hypernephroma

Current status of the therapy of advanced renal carcinoma

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Contact Info

Product

Resources

About